Methotrexato Teva (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for DNA, RNA and protein synthesis. This antiproliferative action reduces the growth of rapidly dividing immune cells and tumor cells, and it also raises extracellular adenosine, contributing to anti‑inflammatory effects.

The dose of Methotrexato Teva is individualized. A qualified prescriber determines the amount, frequency and route based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard regimen is provided here.

Methotrexato Teva is generally contraindicated in pregnancy because methotrexate is known to be teratogenic. It is also not recommended while breastfeeding, as it can be excreted in milk. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To order Methotrexato Teva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexato Teva belongs to the antifolate class, whereas alternatives for rheumatoid arthritis include biologic agents (e.g., TNF‑α inhibitors) and other conventional DMARDs such as leflunomide. Compared with biologics, methotrexate is less expensive and administered by injection, but it may have broader systemic toxicity requiring regular monitoring.

Methotrexato Teva should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided with the product.

Methotrexato Teva is supplied as an injectable solution and is administered by a qualified healthcare professional via epidural, intra‑articular or intramuscular injection, depending on the therapeutic indication and clinical protocol.

The most serious risks include severe liver toxicity (hepatitis or fibrosis), pulmonary fibrosis or interstitial pneumonitis, profound bone‑marrow suppression leading to anemia or neutropenia, and opportunistic infections due to immunosuppression. Patients should be monitored regularly for these complications.

Methotrexato Teva should be avoided in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, pregnant or breastfeeding women, and individuals with pre‑existing pulmonary disease unless benefits outweigh risks and close monitoring is ensured.